Bank Julius Baer & Co. Ltd Zurich Takes Position in Arvinas, Inc. (NASDAQ:ARVN)

Bank Julius Baer & Co. Ltd Zurich bought a new position in Arvinas, Inc. (NASDAQ:ARVN) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 14,480 shares of the company’s stock, valued at approximately $596,000.

Other large investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its position in Arvinas by 96.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,374 shares of the company’s stock worth $27,000 after purchasing an additional 674 shares during the period. BluePath Capital Management LLC bought a new stake in Arvinas in the 3rd quarter worth $28,000. McGlone Suttner Wealth Management Inc. bought a new stake in Arvinas in the 4th quarter worth $75,000. Sectoral Asset Management Inc. grew its holdings in Arvinas by 13.5% in the 3rd quarter. Sectoral Asset Management Inc. now owns 7,010 shares of the company’s stock worth $138,000 after acquiring an additional 835 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in Arvinas by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,746 shares of the company’s stock worth $237,000 after acquiring an additional 1,457 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Price Performance

Shares of NASDAQ ARVN opened at $32.37 on Friday. Arvinas, Inc. has a 1 year low of $13.57 and a 1 year high of $53.08. The stock has a market cap of $2.21 billion, a P/E ratio of -4.98 and a beta of 1.94. The firm has a 50-day moving average of $41.53 and a 200 day moving average of $34.55.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.38). Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. The business had revenue of ($43.10) million for the quarter, compared to analysts’ expectations of $38.91 million. During the same period last year, the business earned ($1.56) earnings per share. Research analysts expect that Arvinas, Inc. will post -5.02 earnings per share for the current fiscal year.

Insider Activity at Arvinas

In other Arvinas news, CFO Sean A. Cassidy sold 1,702 shares of Arvinas stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $80,079.10. Following the completion of the transaction, the chief financial officer now directly owns 181,916 shares of the company’s stock, valued at $8,559,147.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Arvinas news, CFO Sean A. Cassidy sold 1,702 shares of Arvinas stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $80,079.10. Following the completion of the transaction, the chief financial officer now directly owns 181,916 shares of the company’s stock, valued at $8,559,147.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ronald Peck sold 1,699 shares of Arvinas stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the transaction, the insider now directly owns 67,516 shares of the company’s stock, valued at $3,176,627.80. The disclosure for this sale can be found here. Insiders sold a total of 8,597 shares of company stock valued at $404,489 in the last three months. Company insiders own 5.23% of the company’s stock.

Analysts Set New Price Targets

ARVN has been the topic of a number of recent analyst reports. HC Wainwright cut their price target on shares of Arvinas from $90.00 to $87.00 and set a “buy” rating on the stock in a report on Friday, April 12th. Truist Financial reissued a “buy” rating and issued a $65.00 price target on shares of Arvinas in a report on Monday, March 25th. Wedbush raised their price target on shares of Arvinas from $33.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Barclays lifted their target price on shares of Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Finally, The Goldman Sachs Group initiated coverage on shares of Arvinas in a research note on Thursday, February 1st. They set a “buy” rating and a $70.00 target price on the stock. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.73.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.